If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: .
Virginia Cancer Specialists is proud to offer a leading-edge treatment combining the use of PET scans and a new therapy targeting prostate-specific membrane antigen (PSMA)-positive cancer cells in men with prostate cancer, that has spread and become resistant to other forms of treatment.
NEW TREATMENT IDENTIFIES AND TARGETS TREATMENT-RESISTANT CANCER CELLS
This new therapy, which was approved by the US Food and Drug Administration in March 2022, uses a tracing agent (ligand) that attaches to PSMA, a protein on the surface of most prostate cancer cells. If this tracer binds to the cancer cells, they light up on a PET/CT scan and patients are then eligible for a drug called Pluvicto™, which is then injected into the bloodstream to deliver targeted radiation to cancer cells throughout the body that express PSMA. The treatment targets bone, nodal and visceral metastases.
WHO QUALIFIES FOR THIS TREATMENT?
Adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:
- Has spread to other parts of the body (metastatic)
- Has already been treated with other anticancer treatments
Fighting disease at the cellular level, Pluvictotm FAQ’s:
- A targeted therapy that delivers radiation treatment directly to PSMA+ cells, including tumors.
- Given via IV injection or infusion approximately every 6 weeks for up to 6 treatments, depending on how the patient responds.
Pluvictotm helped Men Live Longer: Men with PSMA+ mCRPC who received PluvictoTM plus the best standard of care lived a median of 4 months longer: 15.3 months vs. 11.3 months with BSoC (best standard of care) alone.*
Time without progression: Men treated with Pluvictotm plus BSoC lived longer without their cancer growing or spreading – a median of 8.7 months compared with 3.4 months when on BSoC only.**
Radiation Oncology Team
